Triple DAA regimen cures hepatitis C patients with rapid response in just 3 weeks

Triple DAA regimen cures hepatitis C patients with rapid response in just 3 weeks Direct-acting antiviral agents (DAAs) used in interferon-free regimens have already brought about a revolution in treatment for chronic hepatitis C, but researchers continue to search for … Continue reading

Sofosbuvir-velpatasvir successful in hep C regardless of genotype

Sofosbuvir-velpatasvir successful in hep C regardless of genotype (HealthDay)—Sofosbuvir-velpatasvir is effective for hepatitis C virus (HCV), regardless of genotype, according to three studies published online Nov. 17 in the New England Journal of Medicine. The research was published to coincide … Continue reading